Clinical Trials Search Tool

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2 years and above

Enrollment Opens: 11-23-2021

Enrollment Closes: TBD


This is a double-blind, randomized, vehicle-controlled, Phase 3, multicenter study to evaluate the efficacy and safety of topical
tapinarof cream, 1% compared with vehicle control cream in subjects ages 2 years and above with AD.

Study ID: DMVT-505-3101

To Enroll: Contact Cyn3rgy Research at; 503-907-2179 ext. 4 or visit us on the web at

Posted by: Cyn3rgy Research |